Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: Effects of angiotensin-converting enzyme inhibitors

Journal of the American College of Cardiology

Volumn 37, Issue 6, 2001, Pages 1565-1570

  Delacretaz, Etienne ^a   Ganz, Leonard I ^a   Soejima, Kyoko ^a   Friedman, Peter L ^a   Walsh, Edward P ^a   Triedman, John K ^a   Sloss, Laurence J ^b   Landzberg, Michael J ^b   Stevenson, William G ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BLOOD FLOW VELOCITY; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DRUG EFFECT; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; FIBRINOLYSIS; HEART PROTECTION; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASOMOTOR REFLEX;

ACETYLCHOLINE; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD FLOW VELOCITY; BRADYKININ; CHEST PAIN; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; DRUG SYNERGISM; ECHOCARDIOGRAPHY, DOPPLER; ENALAPRIL; FEMALE; FIBRINOLYSIS; HEART CATHETERIZATION; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PAPAVERINE; TISSUE PLASMINOGEN ACTIVATOR; VASODILATOR AGENTS;

EID: 0035031973     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(01)01202-5     Document Type: Article

References (28)

1. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease
2. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
3. Beneficial effects of bradykinin on myocardial energy metabolism and infarct size
4. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries
5. Endothelium-dependent and -independent responses to vasoactive substances of isolated human coronary arteries
6. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: Evidence for a dynamic storage pool
7. Hemodynamic forces modulate the effect of cytokines on fibrinolytic activity of endothelial cells
8. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin
9. Bradykinin stimulates tissue plasminogen activator release in human vasculature
10. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man
11. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: The TREND (Trial on Reversing Endothelial Dysfunction) study
12. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: A potential role of bradykinin
13. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction
14. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
15. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II
16. Validation of a Doppler guidewire for intravascular measurement of coronary artery flow velocity
17. Bradykinin-induced vasodilatation of human coronary arteries in vivo: Role of nitric oxide and angiotensin-converting enzyme
18. An endothelial storage granule for tissue-type plasminogen activator
19. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature
20. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction
21. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction: HEART study investigators
22. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: Evidence for the fibrinolytic system as an independent primary risk factor
23. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
24. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose
25. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture
26. Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study
27. Endothelial dysfunction, impaired endogenous fibrinolysis and cigarette smoking: A mechanism for arterial thrombosis and myocardial infarction
28. Coronary flow velocity dynamics in normal and diseased arteries